IMMP.US Immutep Ltd ADR

Healthcare Biotechnology USA Stocks
3.48 USD
Close of Nov 15, 2026
2.66 66.39
Market cap
USD 25.6M
P/E
-
P/B
0.61x
ROE
-126.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is IMMP.US undervalued?

Graham number

The Graham number of Immutep Ltd ADR cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Immutep Ltd ADR fundamental analysis

No fundamental analysis for Immutep Ltd ADR yet.

Immutep Ltd ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Immutep Ltd ADR

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment …

Full company profile